Furthermore, as patients with TNBC do not benefit from targeted therapies directed against ERα such as tamoxifen or HER2 with trastuzumab, they have a poorer prognosis and a higher rate of distant recurrence than women with other breast cancer subtypes [6]. This evidence concerns the gene ESR1 and breast carcinoma.